BioSpace News Archive

Shanghai Junshi Biociences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and DotBio Pte. Ltd, a biotech company specialized in next generation antibody therapies, announced that they have entered into a collaboration to develop next-generation antibody therapies.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported the acquisition of its INQUIRE™ Chemical Library to enhance the company’s synthetic lethality drug discovery platform.

Theravance Biopharma, Inc., a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines, will present as follows.

Amneal Pharmaceuticals, Inc. and Saol Therapeutics, a private specialty pharmaceutical company, announced a definitive agreement under which Amneal will acquire Saol’s Baclofen franchise, including Lioresal® and LYVISPAHTM as well as a pipeline product under development.

Alzheon, Inc. announced that Martin Tolar, MD, PhD, the company’s Founder, President and Chief Executive Officer will present at the H.C. Wainwright Bioconnect Conference on January 10th.

Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’, announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study has been achieved.

MannKind Corporation announced that its Chief Executive Officer Michael Castagna, PharmD, will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the year ended December 31, 2021.

Affimed N.V. announced that its Chief Executive Officer Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Standard Time / 16:30 Central European Time.

Progenity, Inc. announced that two presentations with patient data on indicators of efficacy in the treatment of gastrointestinal disorders have been accepted by the 17th Congress of the European Crohn’s and Colitis Organisation, February 16-19, 2022, the world’s largest forum for IBD specialists.